Related references
Note: Only part of the references are listed.Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
Valerie Boige et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study
Po-Huang Lee et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2009)
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
W. Chua et al.
BRITISH JOURNAL OF CANCER (2009)
Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy
Peter H. O'Donnell et al.
CLINICAL CANCER RESEARCH (2009)
Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial
Hanna K. Sanoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysis
Xianlu Zhuo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Thymidylate synthase gene variations: predictive and prognostic markers
Georg Lurje et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Nationwide Cancer Incidence in Korea, 2003 similar to 2005
Young-Joo Won et al.
CANCER RESEARCH AND TREATMENT (2009)
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
Georg Lurje et al.
PHARMACOGENETICS AND GENOMICS (2008)
Pharmacogenetics in colorectal cancer: a systematic review
Silvia Funke et al.
PHARMACOGENOMICS (2008)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk:: a meta-analysis
Yuanchun Li et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2007)
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer
Aimery de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years
A. de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
GSTM1 and GSTT1 polymorphisms, cigarette smoking, and risk of colon cancer:: A population-based case-control study in North Carolina (United States)
K Huang et al.
CANCER CAUSES & CONTROL (2006)
Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers
M Morganti et al.
EUROPEAN JOURNAL OF CANCER (2005)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
DM Kweekel et al.
CANCER TREATMENT REVIEWS (2005)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
D Edler et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
